methyl 6,7-dimethoxyisoquinoline-3-carboxylate | 30740-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: methyl 6,7-dimethoxyisoquinoline-3-carboxylate
• 英文别名: 6,7-dimethoxy-isoquinoline-3-carboxylic acid methyl ester；6,7-Dimethoxy-isochinolin-3-carbonsaeure-methylester；6,7-dimethoxy-3-isoquinolinecarboxylic acid, methyl ester；6,7-dimethoxy-3-isoquinolinecarboxylic acid,methyl ester；3-Carbomethoxy-6,7-dimethoxy-isochinolin
• CAS: 30740-94-4
• 化学式: C₁₃H₁₃NO₄
• 分子量: 247.251
• InChiKey: NVHPOVIVKRQNFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  57.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 6,7-dimethoxyisoquinoline-3-carboxylate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以69%的产率得到6,7-二甲氧基异喹啉-3-羧酸
  参考文献：
  名称：

  [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS
  [FR] COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS CÉRÉBRALES

  摘要：

  这项即时发明描述了包括放射治疗和赛维特鲁内尔在内或不包括地塞米松的药物组合物和给药方案，以及治疗疾病、疾病或症状的方法。

  公开号：

  WO2020077197A1
• 作为产物：
  描述：

  methyl (S)‐6,7‐dimethoxy‐1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylate 在 palladium 10% on activated carbon 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 72.0h， 以64%的产率得到methyl 6,7-dimethoxyisoquinoline-3-carboxylate
  参考文献：
  名称：

  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan analogues as opioid receptor ligands

  摘要：

  A series of 17-cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3 '-carboxamido)morphinan (NAQ) analogues were synthesized and pharmacologically characterized to study their structure-activity relationship at the mu opioid receptor (MOR). The competition binding assay showed two-atom spacer and aromatic side chain were optimal for MOR selectivity. Meanwhile, substitutions at the 1 '- and/or 4 '-position of the isoquinoline ring retained or improved MOR selectivity over the kappa opioid receptor while still possessing above 20-fold MOR selectivity over the delta opioid receptor. In contrast, substitutions at the 6 '- and/or 7 '-position of the isoquinoline ring reduced MOR selectivity as well as MOR efficacy. Among this series of ligands, compound 11 acted as an antagonist when challenged with morphine in warm-water tail immersion assay and produced less significant withdrawal symptoms compared to naltrexone in morphine-pelleted mice. Compound 11 also antagonized the intracellular Ca2+ increase induced by DAMGO. Molecular dynamics simulation studies of 11 in three opioid receptors indicated orientation of the 6 '-nitro group varied significantly in the different 'address' domains of the receptors and played a crucial role in the observed binding affinities and selectivity. Collectively, the current findings provide valuable insights for future development of NAQ-based MOR selective ligands. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.02.055

文献信息

• [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE TUMEURS CÉRÉBRALES
  申请人：INNOCRIN PHARMACEUTICALS INC

  公开号：WO2019182743A1

  公开（公告）日：2019-09-26

  The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders symptoms thereof.

  这项即时发明描述了包含赛维特龙和/或地塞米松的药物组合物和给药方案，以及治疗疾病、疾病症状的方法。
• [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS CÉRÉBRALES
  申请人：INNOCRIN PHARMACEUTICALS INC

  公开号：WO2020077197A1

  公开（公告）日：2020-04-16

  The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.

  这项即时发明描述了包括放射治疗和赛维特鲁内尔在内或不包括地塞米松的药物组合物和给药方案，以及治疗疾病、疾病或症状的方法。
• Efficient and Practical One-Pot Conversions of N-Tosyltetrahydroisoquinolines into Isoquinolines and of N-Tosyltetrahydro-β-carbolines into β-Carbolines through Tandem β-Elimination and Aromatization
  作者：Jing Dong、Xiao-Xin Shi、Jing-Jing Yan、Jing Xing、Qiang Zhang、Sen Xiao

  DOI：10.1002/ejoc.201001153

  日期：2010.12

  An efficient, practical, and general method for conversions of N-tosyltetrahydroisoquinolines (N-tosyl-THIQs) into isoquinolines and of N-tosyltetrahydro-β-carbolines (N-tosyl-THBCs) into β-carbolines is described. Treatment of N-tosyl-THIQs or N-tosyl-THBCs with base in dimethyl sulfoxide afforded dihydroisoquinolines or dihydro-β-carbolines as intermediates, and these were then oxidized in situ by

  描述了一种将 N-tosyltetrahydroisoquinolines (N-tosyl-THIQs) 转化为异喹啉和将 N-tosyltetrahydro-β-carbolines (N-tosyl-THBCs) 转化为 β-咔啉的有效、实用和通用的方法。在二甲基亚砜中用碱处理 N-tosyl-THIQs 或 N-tosyl-THBCs 得到作为中间体的二氢异喹啉或二氢-β-咔啉，然后这些被分子氧原位氧化得到异喹啉或 β-咔啉。产量。两种一锅法转化都是通过串联β-消除和芳构化发生的。
• [EN] NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS D'OXIMES ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2011051478A1

  公开（公告）日：2011-05-05

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGiuR4.

  本发明提供了一般式（I）的新羟肟衍生物，包含它们的药物组合物以及它们用于治疗和/或预防与改变的谷氨酸信号和/或功能有关的疾病，和/或在哺乳动物中改变谷氨酸水平或信号会影响的疾病。本发明进一步提供了一般式（I）的新羟肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新羟肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。
• 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04777252A1

  公开（公告）日：1988-10-11

  Antibacterial activity is exhibited by 3-acylamino-2-oxoazetidines having in the 1-position an activating group of the formula ##STR1## wherein R is ##STR2## and R.sub.4 is ##STR3##

  3-酰氨基-2-氧代杂环丁烷具有抗菌活性，在1-位置带有如下式中的活化基团##STR1##其中R为##STR2##，R.sub.4为##STR3##